Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®

Release Date: February 28, 2017
Expiration Date: February 28, 2018
Media: Internet - based

Activity Overview

State-of-the-art cancer care continues to evolve due to advances in all aspects of patient care, including diagnosis and personalized treatment and management. Through the incorporation of novel diagnostics, systemic therapies, molecular targeted therapies, immunotherapies, and other biotechnological strategies into treatment paradigms, patient outcomes continue to improve along the cancer continuum. The annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow^® (CFS) has brought together over 2000 oncologists, hematologists, radiation oncologists, immunologists, pharmacists, oncology nurses, nurse practitioners, physician assistants, and case managers each year for 34 years, with the aim of educating these disciplines on state-of-the-art treatments across solid and hematologic malignancies and diverse clinical scenarios. At the 34th Annual CFS meeting, our outstanding faculty of leading clinical innovators in virtually every tumor subspecialty provided expert insights on new developments in cancer therapeutics, and offered oncology professionals an opportunity to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials, and emerging developments that define current progress aimed at the goal of the control and cure of cancer.

This activity contains a series of clinical vignettes—focused on breast cancer, kidney cancer, lung cancer, and melanoma—that illustrate the application of data and expert insights from the 2016 CFS in realistic case scenarios that reinforce key learning points from the conference, and facilitate application of these findings to clinical practice to improve patient care.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Ariad Pharmaceuticals, AstraZeneca, Astellas, Celgene Corporation, Clovis Oncology, Eisai, Exelixis, Genomic Health, Incyte, Lilly, Medivation, Merck, NantHealth, Novartis Pharmaceuticals Corporation, Novocure, Pfizer, Pharmacyclics, an AbbVie Company, and Janssen Biotech, administered by Janssen Scientific Affairs, LLC, Taiho Oncology, Takeda Oncology, and Teva Pharmaceuticals

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

CME Activity Table of Contents

• Case 1: Frontline therapy for a patient with stage IV lung adenocarcinoma
  Ben Levy, MD
• Case 2: EGFR-mutation-positive non-small cell lung cancer
  Ben Levy, MD
• Case 3: Frontline therapy for a patient with stage IV, BRAF-mutated melanoma
  Jason Luke, MD
• Case 4: Second-line therapy for metastatic renal cell carcinoma
  Robert Figlin, MD
• Case 5: Residual disease after neoadjuvant therapy for breast cancer
  Debu Tripathy, MD
• Update on immunotherapy in triple-negative breast cancer
  Debu Tripathy, MD

Instructions For This Activity & Receiving Credit You will need to log in to participate in the activity. Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation. At the end of the activity, "educational content/video files" will be available for your reference. In order to receive a CME certificate, participants must complete the activity. Complete the posttest and pass with a score of 70% or higher, complete the evaluation, and then click on the request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

1. Report practice-changing results from clinical trials that impact evolving treatment paradigms in hematologic and solid tumor management
2. Outline testing methods for prognostic and predictive markers that inform personalized care strategies in the treatment of cancer
3. Discuss optimized chemotherapeutic, targeted, and immunotherapy strategies based on clinical trial evidence
4. Describe methods to monitor efficacy and manage treatment-related adverse events in multiple lines of cancer management
5. Place recent clinical trial findings in the context of evolving treatment pathways to improve care for patients with cancer

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Faculty, Staff, and Planners' Disclosures

Faculty

Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Deputy Director
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosure: None

Benjamin P. Levy, MD
Assistant Professor, Icahn School of Medicine
Medical Director, Thoracic Oncology Program
Mount Sinai Health System
Associate Director, Cancer Clinical Trials Office
Mount Sinai Hospital
New York, NY
Disclosure: Genentech, Eli Lilly, AstraZeneca, Celgene,
Biodesix, Pfizer;
Speakers Bureau: Genentech

Jason J. Luke, MD, FACP
Medical Oncologist
Assistant Professor of Medicine
University of Chicago
Chicago, IL
Disclosure: Amgen, Array BioPharma

Debu Tripathy, MD
Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Novartis; Consultant: Nektar Therapeutics,
Novartis, Puma Biotechnology

The staff of Physicians' Education Resource^®, LLC, has no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the any of the companies who provided commercial support for this activity.

CME Provider Contact Information

Physicians’ Education Resource^®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Toll-Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705
info@gotoper.com

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

• A Pentium-based PC or compatible computer
• At least 64MB of RAM
• Windows 95/98/NT/ME/2000/XP/Vista system software
• Screen resolution of 1024 x 786 or larger recommended
• PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

• A PowerPC processor-based Macintosh computer
• At least 64MB of RAM
• Mac OS 7.5 or later
• Screen resolution of 1024 x 786 or larger recommended
• PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise